These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30032204)

  • 1. Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection.
    Scully EP; Rutishauser RL; Simoneau CR; Delagrèverie H; Euler Z; Thanh C; Li JZ; Hartig H; Bakkour S; Busch M; Alter G; Marty FM; Wang CC; Deeks SG; Lorch J; Henrich TJ
    Ann Oncol; 2018 Oct; 29(10):2141-2142. PubMed ID: 30032204
    [No Abstract]   [Full Text] [Related]  

  • 2. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
    Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
    Front Immunol; 2020; 11():1721. PubMed ID: 33072064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer.
    Park SJ; Ye W; Xiao R; Silvin C; Padget M; Hodge JW; Van Waes C; Schmitt NC
    Oral Oncol; 2019 Aug; 95():127-135. PubMed ID: 31345380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.
    Merhi M; Raza A; Inchakalody VP; Nashwan AJJ; Allahverdi N; Krishnankutty R; Uddin S; Zar Gul AR; Al Homsi MU; Dermime S
    Front Immunol; 2018; 9():1769. PubMed ID: 30108590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.
    Vathiotis IA; Johnson JM; Argiris A
    Cancer Treat Rev; 2021 Jun; 97():102192. PubMed ID: 33819755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
    Saada-Bouzid E; Peyrade F; Guigay J
    Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab.
    Ladányi A; Kapuvári B; Papp E; Tóth E; Lövey J; Horváth K; Gődény M; Remenár É
    Head Neck; 2019 May; 41(5):1237-1245. PubMed ID: 30548478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?
    Szturz P; Seiwert TY; Vermorken JB
    J Clin Oncol; 2017 Jul; 35(20):2229-2231. PubMed ID: 28471725
    [No Abstract]   [Full Text] [Related]  

  • 9. Exceptional Response to PD-1 Blockade as First-Line Therapy in Head and Neck Squamous Cell Carcinoma.
    Kumai T; Komatsuda H; Minami Y; Harabuchi Y
    ORL J Otorhinolaryngol Relat Spec; 2020; 82(6):343-350. PubMed ID: 32882699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunocheckpoint inhibition in head and neck squamous cell carcinoma: the current status and progress].
    Huang LL; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):641-647. PubMed ID: 31550852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population.
    Chen WC; Chu PY; Lee YT; Lu WB; Liu CY; Chang PM; Yang MH
    Medicine (Baltimore); 2017 Dec; 96(52):e9519. PubMed ID: 29384959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased PD-1
    Jie HB; Srivastava RM; Argiris A; Bauman JE; Kane LP; Ferris RL
    Cancer Immunol Res; 2017 May; 5(5):408-416. PubMed ID: 28408386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma.
    Oliva M; Spreafico A; Taberna M; Alemany L; Coburn B; Mesia R; Siu LL
    Ann Oncol; 2019 Jan; 30(1):57-67. PubMed ID: 30462163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains?
    Jelinek MJ; Vokes EE
    J Clin Oncol; 2019 Nov; 37(31):2807-2814. PubMed ID: 31483688
    [No Abstract]   [Full Text] [Related]  

  • 15. Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding.
    Andrews LP; Somasundaram A; Moskovitz JM; Szymczak-Workman AL; Liu C; Cillo AR; Lin H; Normolle DP; Moynihan KD; Taniuchi I; Irvine DJ; Kirkwood JM; Lipson EJ; Ferris RL; Bruno TC; Workman CJ; Vignali DAA
    Sci Immunol; 2020 Jul; 5(49):. PubMed ID: 32680952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma.
    Sridharan V; Rahman RM; Huang RY; Chau NG; Lorch JH; Uppaluri R; Haddad RI; Hanna GJ; Schoenfeld JD
    Oral Oncol; 2018 Oct; 85():29-34. PubMed ID: 30220316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab for the treatment of head and neck squamous cell cancer.
    Ho WJ; Mehra R
    Expert Opin Biol Ther; 2019 Sep; 19(9):879-885. PubMed ID: 31317798
    [No Abstract]   [Full Text] [Related]  

  • 18. Eruptive keratoacanthoma with spontaneous regression arising from a cervical squamous cell carcinoma patient treated with nivolumab.
    Fujimura T; Lyu C; Tsukada A; Sato Y; Kambayashi Y; Aiba S
    J Dermatol; 2019 May; 46(5):e177-e178. PubMed ID: 30353913
    [No Abstract]   [Full Text] [Related]  

  • 19. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
    Ferris RL; Licitra L; Fayette J; Even C; Blumenschein G; Harrington KJ; Guigay J; Vokes EE; Saba NF; Haddad R; Ramkumar S; Russell J; Brossart P; Tahara M; Colevas AD; Concha-Benavente F; Lynch M; Li L; Gillison ML
    Clin Cancer Res; 2019 Sep; 25(17):5221-5230. PubMed ID: 31239321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma.
    Tran DC; Colevas AD; Chang AL
    JAMA Dermatol; 2017 Jan; 153(1):92-94. PubMed ID: 27784038
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.